JVJéssica Gardone Vitório

Jéssica Gardone Vitório

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jéssica Gardone Vitório has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hematological and Genotoxic Effects of Subchronic Oral Exposure to a Mancozeb‐Based Fungicide in Female Mice

    by Matheus Henrique Barcelos Figueiredo, Natanael Vaz Crisóstomo Peixoto, Paula Soares Nakamura, Cecília Müller Wodzik, Lucas Ribeiro Maia dos Santos, Fábio Vieira de Andrade Borges, Lara Cândida de Sousa Machado, Jéssica Gardone Vitório, Renata Mazaro e Costa, Mônica Rodrigues Ferreira Machado, et al.

    The extensive use of pesticides in modern agriculture has raised increasing concerns regarding the potential biological effects of repeated exposure to pesticide residues and commercial formulations. Mancozeb is a widely used ethylene‐bis‐dithiocarbamate fungicide; however, information on its hematological and genotoxic effects following repeated oral exposure remains limited, particularly in female models. In this study, we investigated the hematological, genotoxic, welfare‐related, and morphometric effects of subchronic oral exposure to the commercial mancozeb‐based formulation Dithane NT in female Swiss mice. The experimental dose of 200 mg/kg/day was defined as a subchronic oral exposure level for the mammalian assay and was interpreted in relation to available mammalian toxicological and regulatory benchmarks. The Artemia salina assay was used only as a preliminary ecotoxicological screening tool for the commercial formulation and was not applied as a direct interspecies dose‐conversion model. Animals were orally exposed to mancozeb for 30 consecutive days, followed by evaluation of hematological parameters, erythrocyte osmotic fragility, micronucleus frequency in bone marrow erythrocytes, body parameters, and welfare monitoring. Subchronic oral exposure to mancozeb induced a significant increase in micronucleus frequency in bone marrow erythrocytes, indicating a genotoxic response. Hematological evaluation indicated preservation of erythrocyte‐related parameters, leukocyte counts, and erythrocyte membrane stability. Morphometric assessment showed a selective increase in gastrocnemius muscle weight in exposed animals, whereas the remaining evaluated body parameters were not significantly altered. Welfare monitoring identified clinical impairment in a subset of exposed animals, including one euthanasia event before terminal sample collection. Overall, these findings demonstrate that subchronic oral exposure to a mancozeb‐based formulation induces genotoxic damage and a selective morphometric alteration in female mice, even in the absence of overt hematological toxicity.

  • Quantitative proteomic study reveals differential expression of matricellular proteins between fibrous dysplasia and cemento‐ossifying fibroma pathogenesis

    by Filipe Fideles Duarte‐Andrade, Thais dos Santos Fontes Pereira, Jéssica Gardone Vitório, Marina Gonçalves Diniz, Larissa Stefhanne Damasceno Amorim, Arkadiusz Nawrocki, Liza Figueiredo Felicori, Luiz De Marco, Carolina Cavaliéri Gomes, Martin R. Larsen, et al.

    Background: Fibrous dysplasia (FD) and cemento‐ossifying fibroma (COF) are the most common gnathic fibro‐osseous lesions. These diseases exhibit remarkable overlap of several clinicopathological aspects, and differential diagnosis depends on the combination of histopathological, radiographic, and clinical aspects. Their molecular landscape remains poorly characterized, and herein, we assessed their proteomic and phosphoproteomic profiles.Methods: The quantitative differences in protein profile of FD and COF were assessed by proteomic and phosphoproteomic analyses of formalin‐fixed paraffin‐embedded tissue samples. Pathway enrichment analyses with differentially regulated proteins were performed.Results: FD and COF exhibited differential regulation of pathways related to extracellular matrix organization, cell adhesion, and platelet and erythrocytes activities. Additionally, these lesions demonstrated distinct abundance of proteins involved in osteoblastic differentiation and tumorigenesis and differential abundance of phosphorylation of Ser61 of Yes‐associated protein 1 (YAP1).Conclusions: In summary, despite the morphological similarity between these diseases, our results demonstrated that COF and DF present numerous quantitative differences in their proteomic profiles. These findings suggest that these fibro‐osseous lesions trigger distinct molecular mechanisms during their pathogenesis. Moreover, some proteins identified in our analysis could serve as potential biomarkers for differential diagnosis of these diseases after further validation.


  • Metabolic landscape of oral squamous cell carcinoma

    by Jéssica Gardone Vitório, Filipe Fideles Duarte-Andrade, Thaís dos Santos Fontes Pereira, Felipe Paiva Fonseca, Larissa Stefhanne Damasceno Amorim, Roberta Rayra Martins-Chaves, Carolina Cavaliéri Gomes, Gisele André Baptista Canuto, Ricardo Santiago Gomez

    Background Head and neck cancers are the seventh most common type of cancer worldwide, with almost half of the cases affecting the oral cavity. Oral squamous cell carcinoma (OSCC) is the most common form of oral cancer, showing poor prognosis and high mortality. OSCC molecular pathogenesis is complex, resulting from a wide range of events that involve the interplay between genetic mutations and altered levels of transcripts, proteins, and metabolites. Metabolomics is a recently developed sub-area of omics sciences focused on the comprehensive analysis of small molecules involved in several biological pathways by high throughput technologies. Aim of review This review summarizes and evaluates studies focused on the metabolomics analysis of OSCC and oral premalignant disorders to better interpret the complex process of oral carcinogenesis. Additionally, the metabolic biomarkers signatures identified so far are also included. Moreover, we discuss the limitations of these studies and make suggestions for future investigations. Key scientific concepts Although many questions about the metabolic features of OSCC have already been answered in metabolomic studies, further validation and optimization are still required to translate these findings into clinical applications.


  • A review of the molecular profile of benign and malignant odontogenic lesions

    by Filipe Fideles Duarte-Andrade, Jéssica Gardone Vitório, Thaís dos Santos Fontes Pereira, Carolina Cavaliéri Gomes, Ricardo Santiago Gomez


  • First insights for targeted therapies in odontogenic myxoma

    by Núbia Braga Pereira, Victor Coutinho Bastos, Juliana Cristina de Souza, Marina Gonçalves Diniz, Jéssica Gardone Vitório, Gregory Thomas Kitten, Luciana de Oliveira Andrade, Gleide Fernandes de Avelar, Wagner Henriques Castro, Vanessa Fátima Bernardes, et al.

    Odontogenic myxoma (OM) occasionally responds poorly to surgical treatment. The MAPK pathway is constitutively activated in several neoplasms and we aimed to test if the MAPK pathway is activated in OM, in order to pave the way for an alternative therapy for aggressive and recurrent cases.


  • Oral pyogenic granulomas show MAPK/ERK signaling pathway activation, which occurs independently of BRAF, KRAS, HRAS, NRAS, GNA11, and GNA14 mutations

    by Thaís dos Santos Fontes Pereira, Larissa Stefhanne Damasceno de Amorim, Núbia Braga Pereira, Jéssica Gardone Vitório, Filipe Fideles Duarte‐Andrade, Letícia Martins Guimarães, Marina Gonçalves Diniz, Carolina Cavaliéri Gomes, Ricardo Santiago Gomez

    Background: Pyogenic granuloma (PG) is a benign nodular lesion with a prominent vascular component which may affect different sites. Recently, BRAF, KRAS, HRAS, NRAS, GNA11, and GNA14 mutations were reported on PGs of the skin. The present study assessed the role of the MAPK/ERK pathway in oral PG pathogenesis.Methods: Mutations in hotspot regions of genes involved in the MAPK/ERK pathway activation were investigated by Sanger sequencing. The expression of phospho‐ERK1/2 was evaluated by immunohistochemistry.Results: Oral PGs did not show mutations in the sequenced regions of the genes BRAF, KRAS, HRAS, NRAS, GNA11, or GNA14. Our results also showed activation of the MAPK/ERK pathway demonstrated by phospho‐ERK1/2 immunohistochemical positivity.Conclusions: Although oral PG shows MAPK/ERK pathway activation, the driver molecular event remains to be elucidated.


  • Reticular and erosive oral lichen planus have a distinct metabolomic profile: A preliminary study using gas chromatography‐mass spectrometry

    by Aline Fernanda Cruz, Jéssica Gardone Vitório, Filipe Fideles Duarte‐Andrade, Marina Gonçalves Diniz, Gisele André Baptista Canuto, Juliano Simões de Toledo, Felipe Paiva Fonseca, Ana Paula Fernandes, Leiliane Coelho André, Carolina Cavaliéri Gomes, et al.

    Background: Oral Lichen Planus is a chronic inflammatory disorder that affects the oral mucosa, with the reticular and erosive forms representing the primary clinical variants of the disease. Previous studies have shown that metabolic alterations may well be involved in the pathogenesis of the disease; however, the molecular mechanisms related to the clinicopathological differences between erosive and reticular forms remain unknown.Methods: A comparative metabolomic analysis was performed on formalin‐fixed and paraffin‐embedded tissue samples of erosive (n = 6) and reticular (n = 10) oral lichen planus using gas chromatography‐mass spectrometry.Results: The metabolomic analysis showed a distinct profile between the two clinical variants. Five metabolites (cyclohexanamine, glycine, mannitol/sorbitol, methyl palmitate and trehalose) were significantly diminished in erosive oral lichen planus as compared to the reticular form.Conclusions: Reticular and erosive forms of oral lichen planus have a distinct metabolic profile. However, further studies using a large number of fresh tissue samples are necessary to confirm this data.


  • The importance of BRAF‐V600E mutation to ameloblastoma metabolism

    by Filipe Fideles Duarte‐Andrade, André Myller Barbosa Silva, Jéssica Gardone Vitório, Gisele André Baptista Canuto, Sara Ferreira Santos Costa, Marina Gonçalves Diniz, Ana Paula Fernandes, Juliano Simões de Toledo, Leiliane Coelho André, Carolina Cavaliéri Gomes, et al.

    Background: Ameloblastoma is a locally infiltrative, aggressive epithelial odontogenic neoplasm. BRAF‐V600E mutation is frequently found in this tumor and has a pivotal role in its pathogenesis, but the consequences of this alteration need to be addressed. An untargeted metabolomics approach was applied to verify whether metabolic disturbances are related to tumor biology and whether BRAF‐V600E mutation contributes to these alterations.Methods: Formalin‐fixed and paraffin‐embedded tissue specimens from thirteen ameloblastoma and six dental follicles were included in this study. BRAF mutational status was determined by competitive allele‐specific real‐time PCR. Metabolite extracts were analyzed using gas chromatography coupled to mass spectrometry. Univariate and multivariate statistical methods were employed to compare the metabolic profiles of the samples.Results: The abundance of eleven metabolites was significantly higher in ameloblastoma in relation to dental follicles, including amino acids, fatty acids, carbohydrates, inorganic acids, and organoheterocyclic compounds. The presence of BRAF‐V600E mutations in ameloblastoma was related to decreased levels of glycerol in comparison with tumors carrying only wild‐type alleles of this gene. No metabolic differences were observed between recurrent and primary manifestations of ameloblastoma.Conclusions: Ameloblastoma exhibits a distinct metabolic profile from normal odontogenic epithelium. BRAF‐V600E may contribute to metabolic alterations in ameloblastoma. Collectively, our findings suggest that metabolic alterations might play a role in tumor pathogenesis.


  • Open Access

    Evaluation of three recombinant proteins for the development of ELISA and immunochromatographic tests for visceral leishmaniasis serodiagnosis

    by Anna Raquel Ribeiro dos Santos, Ângela Vieira Serufo, Maria Marta Figueiredo, Lara Carvalho Godoi, Jéssica Gardone Vitório, Andreza Pain Marcelino, Daniel Moreira de Avelar, Fernandes Tenório Gomes Rodrigues, George Luiz Lins Machado-Coelho, Fernanda Alvarenga Cardoso Medeiros, et al.

    Key words: visceral leishmaniasis; recombinant proteins; diagnosis; ELISA; immunochromatographic test